Currently approved vaccines against SARS-CoV-2 target the trimeric spike glycoprotein, which plays a major role in initiating viral infection via the interaction of its receptor-binding domain (RDB) with angiotensin-converting enzyme 2 (ACE-2) [67]. The gene discussed is ACE2; the disease is viral infectious disease.